Express Inc. (NYSE:EXPR) represented a move of 3.93 percent or $-0.33 per share and closed its previous day trading session at $7.14. 1.43 Million Shares were traded in the last trading session with an Average Volume of 3.02 Million Shares. The stock currently has a Market Capitalization of 562.67 Million.
Express, Inc. is a specialty retailer of women’s and men’s apparel in the United States. The Company operates retail outlets in high-traffic shopping malls, lifestyle centers and street locations across the United States. It also sells its products through its e-commerce website, express.com. Express targets women and men between 20 and 30 years of age. The Company offers its customers an edited assortment of apparel and accessories to address fashion needs across multiple aspects of their lifestyles, including work, casual and going-out occasions. Express, Inc. is headquartered in Columbus, Ohio.
The stock traded between $ 5.28 and $11.69 over 1-Year time period showing its price to sales ratio of 0.27. Express Inc. (NYSE:EXPR) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-18.66 and 200-Day Simple Moving Average of $-2.77. Its Price to Free Cash Flow is 3.22 and Price to Book of 0.88.
Analyst’s recommended the stock as 3 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Express Inc. (NYSE:EXPR) reported its Actual EPS of $0.08/share. The analysts offering Earnings Estimates for the company were believing that Express Inc. could bring EPS of $0.08/share. The difference between Actual EPS and Estimated EPS was 0 Percent. Thus showing an Earnings Surprise of 0 Percent.
Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
In the last trading session, Atara Biotherapeutics, Inc. (NASDAQ:ATRA) added its value by 7.33% closing at the price of $48.35. The stock currently has market capitalization of 1.3 Billion, with average volume of 819.4 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is showing beta of 2.33. This particular value of beta suggests that Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has historically moved 233% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is at $-3.47.
The stock currently has RSI of 75.67. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California.
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) topped its 52-week high price of $49.90 on 02/14/18 and 52-Week Low Price of $11.80 on 06/15/17. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 14.47% and monthly volatility of 10.88% respectively.